title: Abiraterone and increased survival in metastatic prostate cancer.
abstract: BACKGROUND
  Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.
  
  
  METHODS
  We randomly assigned, in a 2:1 ratio, 1195 patients who had previously received docetaxel to receive 5 mg of prednisone twice daily with either 1000 mg of abiraterone acetate (797 patients) or placebo (398 patients). The primary end point was overall survival. The secondary end points included time to prostate-specific antigen (PSA) progression (elevation in the PSA level according to prespecified criteria), progression-free survival according to radiologic findings based on prespecified criteria, and the PSA response rate.
  
  
  RESULTS
  After a median follow-up of 12.8 months, overall survival was longer in the abiraterone acetate-prednisone group than in the placebo-prednisone group (14.8 months vs. 10.9 months; hazard ratio, 0.65; 95% confidence interval, 0.54 to 0.77; P<0.001). Data were unblinded at the interim analysis, since these results exceeded the preplanned criteria for study termination. All secondary end points, including time to PSA progression (10.2 vs. 6.6 months; P<0.001), progression-free survival (5.6 months vs. 3.6 months; P<0.001), and PSA response rate (29% vs. 6%, P<0.001), favored the treatment group. Mineralocorticoid-related adverse events, including fluid retention, hypertension, and hypokalemia, were more frequently reported in the abiraterone acetate-prednisone group than in the placebo-prednisone group.
  
  
  CONCLUSIONS
  The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy. (Funded by Cougar Biotechnology; COU-AA-301 ClinicalTrials.gov number, NCT00638690.).
authors: Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom. johann.de-bono@icr.ac.uk
authors: Johann S
authors: JS
authors: de Bono
authors: Christopher J
authors: CJ
authors: Logothetis
authors: Arturo
authors: A
authors: Molina
authors: Karim
authors: K
authors: Fizazi
authors: Scott
authors: S
authors: North
authors: Luis
authors: L
authors: Chu
authors: Kim N
authors: KN
authors: Chi
authors: Robert J
authors: RJ
authors: Jones
authors: Oscar B
authors: OB
authors: Goodman
authors: Fred
authors: F
authors: Saad
authors: John N
authors: JN
authors: Staffurth
authors: Paul
authors: P
authors: Mainwaring
authors: Stephen
authors: S
authors: Harland
authors: Thomas W
authors: TW
authors: Flaig
authors: Thomas E
authors: TE
authors: Hutson
authors: Tina
authors: T
authors: Cheng
authors: Helen
authors: H
authors: Patterson
authors: John D
authors: JD
authors: Hainsworth
authors: Charles J
authors: CJ
authors: Ryan
authors: Cora N
authors: CN
authors: Sternberg
authors: Susan L
authors: SL
authors: Ellard
authors: Aude
authors: A
authors: Fléchon
authors: Mansoor
authors: M
authors: Saleh
authors: Mark
authors: M
authors: Scholz
authors: Eleni
authors: E
authors: Efstathiou
authors: Andrea
authors: A
authors: Zivi
authors: Diletta
authors: D
authors: Bianchini
authors: Yohann
authors: Y
authors: Loriot
authors: Nicole
authors: N
authors: Chieffo
authors: Thian
authors: T
authors: Kheoh
authors: Christopher M
authors: CM
authors: Haqq
authors: Howard I
authors: HI
authors: Scher
references: Clin Cancer Res. 2008 Oct 1;14(19):6302-9
references: 18829513
references: Cancer Res. 2006 Mar 1;66(5):2815-25
references: 16510604
references: CA Cancer J Clin. 2002 May-Jun;52(3):154-79
references: 12018929
references: Cancer Invest. 1994;12(3):336-42
references: 8187012
references: Cancer Cell. 2009 Dec 8;16(6):458-62
references: 19962664
references: Clin Cancer Res. 2004 Jan 15;10(2):440-8
references: 14760063
references: Lancet. 2010 Oct 2;376(9747):1147-54
references: 20888992
references: J Steroid Biochem Mol Biol. 1997 Mar;60(5-6):347-51
references: 9219927
references: N Engl J Med. 2010 Jul 29;363(5):411-22
references: 20818862
references: CA Cancer J Clin. 2008 Jul-Aug;58(4):196-213
references: 18502900
references: J Urol. 2011 Mar;185(3):787-94
references: 21239012
references: Clin Cancer Res. 2005 Jul 1;11(13):4653-7
references: 16000557
references: Am J Clin Oncol. 1982 Dec;5(6):649-55
references: 7165009
references: CA Cancer J Clin. 2010 May-Jun;60(3):194-201
references: 20124400
references: Cancer. 1999 Mar 1;85(5):1186-96
references: 10091805
references: BJU Int. 2005 Dec;96(9):1241-6
references: 16287438
references: J Clin Oncol. 2010 Oct 10;28(29):e560-1; author reply e562
references: 20805462
references: J Urol. 1984 Oct;132(4):693-6
references: 6471215
references: Cancer Res. 2007 May 15;67(10):5033-41
references: 17510436
references: J Natl Cancer Inst. 2010 Jan 6;102(1):39-46
references: 19996060
references: J Med Chem. 1998 Dec 31;41(27):5375-81
references: 9876107
references: N Engl J Med. 1989 Aug 17;321(7):419-24
references: 2503724
references: Cancer Res. 2008 Jun 1;68(11):4447-54
references: 18519708
references: Urology. 1997 Dec;50(6):920-8
references: 9426724
references: Endocr Rev. 2011 Feb;32(1):81-151
references: 21051590
references: J Clin Endocrinol Metab. 2006 Oct;91(10):3850-6
references: 16882745
references: J Med Chem. 1995 Jun 23;38(13):2463-71
references: 7608911
references: Clin Oncol (R Coll Radiol). 2007 Sep;19(7):523-7
references: 17566723
references: J Urol. 2006 Jan;175(1):27-34
references: 16406864
references: Cancer Res. 2008 Aug 1;68(15):6407-15
references: 18676866
references: Nat Med. 2004 Jan;10(1):33-9
references: 14702632
references: J Clin Oncol. 2010 Mar 20;28(9):1496-501
references: 20159814
references: Clin Cancer Res. 2004 Apr 15;10(8):2705-8
references: 15102674
references: J Clin Oncol. 2009 Aug 10;27(23):3742-8
references: 19470933
references: J Clin Endocrinol Metab. 2004 Jan;89(1):49-60
references: 14715827
references: J Clin Oncol. 1999 Nov;17(11):3461-7
references: 10550143
references: N Engl J Med. 2004 Oct 7;351(15):1502-12
references: 15470213
references: J Clin Oncol. 2010 Mar 20;28(9):1489-95
references: 20159823
references: J Clin Oncol. 2010 Mar 20;28(9):1481-8
references: 20159824
references: J Clin Oncol. 2005 Nov 10;23(32):8253-61
references: 16278481
references: J Clin Oncol. 2008 Mar 1;26(7):1148-59
references: 18309951
references: Pain. 1983 Oct;17(2):197-210
references: 6646795
references: Am J Pathol. 2004 Jan;164(1):217-27
references: 14695335
references: J Clin Oncol. 2008 Oct 1;26(28):4563-71
references: 18645193
references: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references: 10655437